Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Cost of Revenue: 2017-2024

Historic Cost of Revenue for Ptc Therapeutics (PTCT) over the last 8 years, with Dec 2024 value amounting to $57.4 million.

  • Ptc Therapeutics' Cost of Revenue rose 45.47% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year decrease of 19.77%. This contributed to the annual value of $57.4 million for FY2024, which is 12.35% down from last year.
  • Ptc Therapeutics' Cost of Revenue amounted to $57.4 million in FY2024, which was down 12.35% from $65.5 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Cost of Revenue ranged from a high of $65.5 million in FY2023 and a low of $18.9 million during FY2020.
  • Its 3-year average for Cost of Revenue is $55.9 million, with a median of $57.4 million in 2024.
  • Per our database at Business Quant, Ptc Therapeutics' Cost of Revenue spiked by 70.67% in 2021 and then decreased by 12.35% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Cost of Revenue (Yearly) stood at $18.9 million in 2020, then soared by 70.67% to $32.3 million in 2021, then spiked by 38.20% to $44.7 million in 2022, then soared by 46.57% to $65.5 million in 2023, then declined by 12.35% to $57.4 million in 2024.